<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632927</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457FDE04</org_study_id>
    <secondary_id>2019-004246-15</secondary_id>
    <nct_id>NCT04632927</nct_id>
  </id_info>
  <brief_title>Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment</brief_title>
  <acronym>AgAIN</acronym>
  <official_title>A 28-week, Randomized, Double-blind, Active Controlled, Multicenter Study to Evaluate the Efficacy of Subcutaneously Administered Secukinumab Compared to Ustekinumab in Adult Patients With Psoriatic Arthritis and Failure of TNFα- Inhibitor Treatment (AgAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of secukinumab and&#xD;
      ustekinumab in patients with active psoriatic arthritis who showed failure to previous&#xD;
      TNFα-inhibitor treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">April 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>The disability assessment component of the HAQ assesses a subjects level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving PASI 90</measure>
    <time_frame>28 Weeks</time_frame>
    <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI 90 represents an improvement in the PASI score of at least 90% as compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient's assessment of pain on VAS</measure>
    <time_frame>28 Weeks</time_frame>
    <description>Patient Reported Outcome: Patient's assessment of pain measures an individual's level of pain by marking a vertical tick on a horizontal VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Tender Joint Count (TJC) 68</measure>
    <time_frame>28 Weeks</time_frame>
    <description>TJC is determined by physical examination of 68 joint counts that are assessed for tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Swollen Joint Count (SJC) 66</measure>
    <time_frame>28 Weeks</time_frame>
    <description>SJC is determined by physical examination of 66 joint counts that are classified as either swollen or not swollen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving PASI 100</measure>
    <time_frame>28 Weeks</time_frame>
    <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI 100 represents an improvement in the PASI score of at least 100% as compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving PASI 75</measure>
    <time_frame>28 Weeks</time_frame>
    <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI 75 represents an improvement in the PASI score of at least 75% as compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient's Global Assessment of Disease Activity on VAS</measure>
    <time_frame>28 Weeks</time_frame>
    <description>Patient Reported Outcome: Patient's global disease activity is recorded using a horizontal VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS</measure>
    <time_frame>28 Weeks</time_frame>
    <description>Patient Reported Outcome: Patient's Global Assessment of Psoriasis and Arthritis Disease Activity is recorded using a horizontal VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Minimal Disease Activity (MDA)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>MDA is achieved if 5 of 7 outcome measures are fulfilled: ≤ 1 TJC; ≤ 1 SJC; PASI ≤ 1 or BSA ≤3%, patient's assessment of pain on VAS ≤ 15; patient's global assessment of disease activity ≤ 20 (VAS);HAQ-DI ≤ 0.5; tender enthesial points ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Leeds Enthesitis Index (LEI)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>The LEI was developed for the use in PsA and measures enthesitis at 6 sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Leeds Dactylitis Index (LDI)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>The LDI measures the severity of dactylitis. The ratio of the circumfence of each affected digit to the circumfence of the digit on the opposite hand or foot is measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Psoriatic Arthritis Quality of Life (PsAQoL)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>Patient Reported Outcome: PsAQoL is a patient-administered 20-item questionnaire to evaluate the effect of PsA on a patient's quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>Patient Reported Outcome: FACIT-Fatigue is a questionnaire that measures an individual's level of fatigue and its impact upon daily activities and function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Dermatology Life Quality Index (DLQI) 0/1</measure>
    <time_frame>28 Weeks</time_frame>
    <description>Patient Reported Outcome: DLQI is a patient-administered and validated quality-of-life questionnaire that covers 6 domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety and tolerability of secukinumab 300 mg s.c. compared to ustekinumab</measure>
    <time_frame>28 Weeks</time_frame>
    <description>The incidence of clinically significant abnormal laboratory values/test results and adverse, serious adverse events (by review of values outside clinically notable ranges, significant changes from Baseline or the previous visit, or values, which are considered to be non-typical in participants with underlying disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_label>Ustekinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_label>Ustekinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PsA as classified by CASPAR criteria for at least 6 months before&#xD;
             randomization.&#xD;
&#xD;
          -  Active PsA at baseline defined as ≥ 3 tender joints out of 68 and ≥ 3 swollen joints&#xD;
             out of 66 (dactylitis of a digit counts as one joint each).&#xD;
&#xD;
          -  Inadequate response or intolerance to previous or current treatment with at least one&#xD;
             TNFα inhibitor&#xD;
&#xD;
          -  Inadequate response or intolerance to conventional disease modifying anti-rheumatic&#xD;
             drugs (cDMARDs)&#xD;
&#xD;
          -  Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm&#xD;
             diameter and/or nail changes consistent with psoriasis and/or documented history of&#xD;
             plaque psoriasis.&#xD;
&#xD;
          -  Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies negative&#xD;
             at screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women,&#xD;
&#xD;
          -  Previous exposure to secukinumab, ustekinumab or any other biologic drug directly&#xD;
             targeting IL-17, IL-17 receptor, IL-12 or IL-23.&#xD;
&#xD;
          -  Patients for whom the use of secukinumab or ustekinumab is contraindicated.&#xD;
&#xD;
          -  Use of any other investigational drug. Previous treatment with any cell-depleting&#xD;
             therapies including but not limited to anti-CD20 or investigational agents&#xD;
&#xD;
          -  Evidence of ongoing infectious or malignant process&#xD;
&#xD;
          -  Subjects receiving high potency opioid analgesics&#xD;
&#xD;
          -  Ongoing use of prohibited psoriasis treatments/medications&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rendsburg</city>
        <state>Schleswig Holstein</state>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Bramstedt</city>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Pyrmont</city>
        <zip>31812</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ehringshausen</city>
        <zip>35630</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gommern</city>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>D-67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81541</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puettlingen/saar</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ratingen</city>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>July 10, 2021</last_update_submitted>
  <last_update_submitted_qc>July 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>Psoriasis Arthropathica</keyword>
  <keyword>Psoriatic Arthropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

